Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06637306 · ClinicalTrials.gov registry record · Early Phase 1

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

A Early Phase 1 study of TNBC - Triple-Negative Breast Cancer and Locally Advanced Triple Negative Breast Cancer, sponsored by Rima Patel.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT06637306 is a Early Phase 1 study of TNBC - Triple-Negative Breast Cancer and Locally Advanced Triple Negative Breast Cancer that is actively recruiting participants, run by Rima Patel. The registered enrollment target is 15 participants, below the 481-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06637306, a Early Phase 1 study of TNBC - Triple-Negative Breast Cancer and Locally Advanced Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Rima Patel.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety of neoadjuvant dupilumab and pembrolizumab plus weekly paclitaxel and carboplatin as measured by the proportion of severe immune-related adverse events (irAEs) in patients with locally advanced TNBC. Secondary Objectives: To determine the rates of pathologic complete response with the addition of dupilumab to NAC and pembrolizumab; to determine the rate of residual cancer burden 0-1; to estimate the recurrence-free survival and overall survival; to assess the toxicity of the combination of dupilumab, pembrolizumab, and paclitaxel-carboplatin.

Conditions Studied

TNBC - Triple-Negative Breast Cancer Locally Advanced Triple Negative Breast Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Dupilumab
  • DRUG Paclitaxel

Study Locations (1)

New York

  • Mount Sinai Health System - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-03-05
Est. Completion 2027-06-01
Phase Early Phase 1

Sponsor

Rima Patel

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06637306

The ClinicalTrials.gov registry entry for NCT06637306 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Rima Patel, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with TNBC - Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT06637306 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06637306 about?

NCT06637306 is a clinical study titled "Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer". Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety of neoadjuvant dupilumab and pembrolizumab plus weekly paclitaxel and carboplatin as measured by th...

What is the current status of trial NCT06637306?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2025-03-05. Estimated completion is 2027-06-01.

What conditions does trial NCT06637306 study?

This clinical trial studies the following conditions: TNBC - Triple-Negative Breast Cancer, Locally Advanced Triple Negative Breast Cancer.

What interventions are being tested in trial NCT06637306?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Dupilumab (DRUG), Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06637306?

This trial is sponsored by Rima Patel, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06637306 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for TNBC - Triple-Negative Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

TNBC - Triple-Negative Breast Cancer

All registered trials for this condition

Locally Advanced Triple Negative Breast Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.